Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/24/2019
Start Date:August 28, 2017
End Date:August 28, 2020
Contact:Michael Zelefsky, MD
Email:zelefskm@mskcc.org
Phone:212-639-6802

Use our guide to learn which trials are right for you!

A Phase I Feasibility Study of Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR Image-Guided, Intensity-Modulated Radiotherapy

The purpose of the study is to find out the feasibility and effects of ultra-hypofractionated
radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate
risk prostrate cancer.


Inclusion Criteria:

- Intermediate risk prostate cancer patients will be eligible for this study. Risk
groups will be assigned as per NCCN guidelines. Intermediate risk patients will be
defined as:

- PSA 10-20 ng/ml or

- Gleason score = 7 or

- Clinical stage T2b/T2c

- Additionally, patients will be required to meet the following criteria:

- Age ≥ 18

- KPS ≥ 80

- Prostate size ≤ 60cc

- Presence of a prostatic lesion with maximum dimension of >/= 0.5cm and no more
than two additional disease foci, each with a maximum dimension less than that of
the dominant lesion.

- International Prostrate Symptom Score ≤ 15

- Subjects must fill out the standard MRI screening form and satisfy all MRI
screening criteria

Exclusion Criteria:

- Prior androgen deprivation therapy for prostate cancer

- Evidence of metastatic disease on bone scan or MRI/CT

- MRI ineligibility due to the presence of a cardiac pacemaker, defibrillator or other
implanted metallic or electronic device which is considered MR unsafe, severe
claustrophobia or inability to lie flat for the duration of the study, etc.

- Metallic hip implant, metallic implant or device in the pelvis that might distort the
local magnetic field and compromise quality of MP-MRI.

- Lateral pelvic separation greater than 50 cm and/or anterior-posterior separation
greater than 35 cm which are incompatible with MRCAT reconstruction

- Contra-indications to receiving gadolinium contrast

- KPS < 80

- Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease.

- Prior history of transurethral resection of the prostate

- Prior history of chronic prostatitis

- Prior history of urethral stricture

- Prior history of pelvic irradiation

- History of inflammatory bowel disease

- Unable to give informed consent

- Unable to complete quality of life questionnaires

- Abnormal complete blood count. Any of the following

- Platelet count less than 75,000/ml

- Hb level less than 10 gm/dl

- WBC less than 3.5/ml

- Abnormal renal function tests (creatinine > 1.5)
We found this trial at
8
sites
500 Westchester Avenue
Harrison, New York 10604
Phone: 212-639-6802
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Basking Ridge, New Jersey 07920
Phone: 212-639-6802
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 212-639-6802
?
mi
from
Commack, NY
Click here to add this to my saved trials
480 Red Hill Road
Middletown, New Jersey 07748
Phone: 212-639-6802
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
Montvale, New Jersey 07645
Phone: 212-639-6802
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Michael Zelefsky, MD
Phone: 212-639-6802
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 212-639-6802
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 212-639-6802
?
mi
from
Uniondale, NY
Click here to add this to my saved trials